Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Quinn

Showing results (471-480 of 635) with videos related to

Pageof 64
Sort By:
Disease Models & Mechanisms|May 21, 2011
A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drugPhilip F Copenhaver, Thimmappa S Anekonda, Derek Musashe, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 6, 2023
Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panelMarwan N Sabbagh, Angela Taylor, Douglas Galasko, et al.
Archives of Neurology|March 21, 2012
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measuresDouglas R Galasko, Elaine Peskind, Christopher M Clark, et al.
Journal of Environmental Management|July 6, 2015
A cloud based tool for knowledge exchange on local scale flood riskM E Wilkinson, E Mackay, P F Quinn, et al.
Journal of Clinical and Experimental Neuropsychology|June 11, 2019
Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinson's diseaseKrista Specketer, Cyrus P Zabetian, Karen L Edwards, et al.
Schizophrenia Research|November 10, 2009
Schizophrenia and the city: A review of literature and prospective study of psychosis and urbanicity in IrelandBrendan D Kelly, Eadbhard O'Callaghan, John L Waddington, et al.
Cancer Chemotherapy and Pharmacology|January 23, 2014
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumorsEdward Sausville, Patricia Lorusso, Michael Carducci, et al.
Journal of Alzheimer'S Disease : JAD|April 27, 2005
Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer diseaseJing Zhang, Dave R Goodlett, Joseph F Quinn, et al.
ACS Macro Letters|May 25, 2022
Overcoming Surfactant-Induced Morphology Instability of Noncrosslinked Diblock Copolymer Nano-Objects Obtained by RAFT Emulsion PolymerizationNghia P Truong, Cheng Zhang, Tuan A H Nguyen, et al.
Neurology|August 19, 2007
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up studyG Li, I Sokal, J F Quinn, et al.
Pageof 64

Showing results (471-480 of 635) with videos related to

Sort By:
Pageof 64
Disease Models & Mechanisms|May 21, 2011
A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drugPhilip F Copenhaver, Thimmappa S Anekonda, Derek Musashe, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 6, 2023
Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panelMarwan N Sabbagh, Angela Taylor, Douglas Galasko, et al.
Archives of Neurology|March 21, 2012
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measuresDouglas R Galasko, Elaine Peskind, Christopher M Clark, et al.
Journal of Environmental Management|July 6, 2015
A cloud based tool for knowledge exchange on local scale flood riskM E Wilkinson, E Mackay, P F Quinn, et al.
Journal of Clinical and Experimental Neuropsychology|June 11, 2019
Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinson's diseaseKrista Specketer, Cyrus P Zabetian, Karen L Edwards, et al.
Schizophrenia Research|November 10, 2009
Schizophrenia and the city: A review of literature and prospective study of psychosis and urbanicity in IrelandBrendan D Kelly, Eadbhard O'Callaghan, John L Waddington, et al.
Cancer Chemotherapy and Pharmacology|January 23, 2014
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumorsEdward Sausville, Patricia Lorusso, Michael Carducci, et al.
Journal of Alzheimer'S Disease : JAD|April 27, 2005
Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer diseaseJing Zhang, Dave R Goodlett, Joseph F Quinn, et al.
ACS Macro Letters|May 25, 2022
Overcoming Surfactant-Induced Morphology Instability of Noncrosslinked Diblock Copolymer Nano-Objects Obtained by RAFT Emulsion PolymerizationNghia P Truong, Cheng Zhang, Tuan A H Nguyen, et al.
Neurology|August 19, 2007
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up studyG Li, I Sokal, J F Quinn, et al.
Pageof 64